“Do not impact fertility.” That was the headline assurance in a February 2021 joint statement from the American College of Obstetricians and Gynecologists and two other reproductive medicine organizations. Yet, its text acknowledged that fertility had not been specifically studied in Pfizer’s COVID-19 vaccine clinical trials. It described loss of fertility as scientifically unlikely. The statement is reproduced in ASRM’s February 2021 guidance.
A conclusion and an expectation are different things. Patients deserved to hear the difference. As a surgeon, I believe a credible safety concern deserves explanation before causation is settled. Informed consent requires discussing uncertainty while patients still have a decision to make.
Spine surgery offers a consequential precedent. In 2013, approximately eleven years after Infuse’s initial Food and Drug Administration approval in 2002, two independent Yale Open Data Access analyses raised concerns about cancer following use of its bone-growth protein, rhBMP-2.
A ‘WEIRD’ LESBIAN BAR JUST DROPPED ITS MASK MANDATE — AND LIBERALS ARE MELTING DOWN
One estimated nearly twice the cancer risk — a relative risk of 1.98 — without reaching statistical significance. The other found a statistically significant increase, with a relative risk of 3.45 at 24 months of patient follow-up. Although cancer events were few, that did not negate a serious concern.
Medtronic voluntarily opened its data to independent criticism through YODA and funded the reviews. Independent investigators gained access to participant-level data and unpublished material. Reviewers documented selective reporting and underreporting in earlier publications, concluding that earlier disclosure would have better informed clinicians and patients.
In 2014, Medtronic agreed to pay $22 million to resolve broader Infuse product liability claims involving approximately 950 claimants, without admitting liability.
Florida’s Oct. 1 lawsuit against Pfizer and CEO Albert Bourla brings that disclosure obligation into immediate focus. It alleges that safety assurances omitted material information, including reproductive concerns and limitations in pregnancy research. These are allegations, not adjudicated findings. The question deserves an answer: Did public assurances faithfully represent the evidence available when they were made?
Pfizer’s reproductive study reported mean preimplantation loss of 9.77% in vaccinated rats versus 4.09% in controls, a statistically significant difference of more than twofold.
Investigators considered the difference nonadverse, citing historical control ranges, higher ovulation counts, and similar implantation and offspring counts. Both the finding and its interpretation belong in the discussion.
The measure compares estimated ovulation counts with implantation sites. It cannot distinguish failed fertilization from embryonic loss before implantation.
Humans typically carry one fetus through a much longer gestation, while laboratory rodents reproduce rapidly and bear litters. Those differences matter when interpreting reproductive findings and assessing their human relevance.
Animal studies exist to protect humans.
A study counting miscarriages in recognized pregnancies does not directly measure losses occurring before implantation. Reassurance should identify which reproductive outcomes were studied and which questions those studies could answer.
Women’s reports of menstrual changes likewise warranted investigation. In October 2022, European regulators recommended adding heavy menstrual bleeding to Pfizer’s and Moderna’s product information, concluding that a causal association was reasonably possible. A reproductive effect need not cause infertility to matter. Reassurance about fertility alone does not address the full range of reproductive concerns.
Pregnancy communication raises a related concern. In January 2021, Dr. Anthony Fauci privately discussed whether reactions following a second dose “theoretically could be associated with miscarriage in the 1st trimester.” The exchange included reassurance about animal toxicology.
On Feb. 3, Fauci publicly reported no red flags among vaccinated pregnant women, qualifying the assessment as preliminary. Patients deserved an explanation of the specific concern, the available evidence, and the limits of that early assessment.
Pfizer’s subsequent pregnancy trial administered the first dose at 24–34 weeks of gestation, excluding the first trimester, when approximately 80% of pregnancy losses occur. Its design could not directly assess the early-pregnancy concern Fauci had discussed. Why exclude the first trimester, and what evidence supported first-trimester assurances when they were made?
A Norwegian registry-based case-control study found no increased miscarriage odds associated with recent vaccination, while a U.S.–Canadian prospective cohort study found no appreciable reduction in conception rates associated with vaccination. Both were observational, providing weaker evidence of causality than randomized trials.
Pfizer should follow Medtronic’s example by providing qualified independent researchers access to complete reports, protocols, and participant-level data, with appropriate privacy protections. The review should identify which assurances were supported at the time, which exceeded the evidence, and whether material uncertainties were adequately disclosed.
FAUCI’S FALL: ‘THE SCIENCE’ PLEADS THE FIFTH
The standard is straightforward: explain credible concerns, their evidentiary strength, expected benefits, and consequences of declining treatment. Update that explanation as knowledge improves.
Physicians can recommend treatment while acknowledging uncertainty. Patients deserve truth and candor before deciding. That is what informed consent requires.
Morgan P. Lorio is a retired orthopedic spine surgeon, healthcare policy author, hospital chaplain, and former president of the International Society for the Advancement of Spine Surgery.